Compare TRAK & CRDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TRAK | CRDL |
|---|---|---|
| Founded | 1990 | 2017 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 186.2M | 154.1M |
| IPO Year | 1996 | 2017 |
| Metric | TRAK | CRDL |
|---|---|---|
| Price | $10.44 | $1.23 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 101.7K | ★ 367.9K |
| Earning Date | 05-14-2026 | 05-14-2026 |
| Dividend Yield | ★ 0.90% | N/A |
| EPS Growth | ★ 20.69 | N/A |
| EPS | ★ 0.28 | N/A |
| Revenue | ★ $21,007,076.00 | N/A |
| Revenue This Year | $6.61 | N/A |
| Revenue Next Year | $10.04 | N/A |
| P/E Ratio | $36.82 | ★ N/A |
| Revenue Growth | ★ 4.84 | N/A |
| 52 Week Low | $6.94 | $0.88 |
| 52 Week High | $22.17 | $1.71 |
| Indicator | TRAK | CRDL |
|---|---|---|
| Relative Strength Index (RSI) | 62.93 | 38.48 |
| Support Level | $10.03 | $0.94 |
| Resistance Level | $10.64 | $1.38 |
| Average True Range (ATR) | 0.46 | 0.06 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 83.33 | 5.26 |
ReposiTrak Inc is a software-as-a-service (SaaS) company based in Murray, Utah, specializing in supply chain management solutions for retailers, suppliers, and wholesalers, prominently in the food industry. The company offers three main product suites: ReposiTrak Compliance Management, ReposiTrak Traceability Network, and ReposiTrak Supply Chain Solutions. These platforms help customers comply with food safety regulations, manage supplier compliance documentation, trace products through the supply chain, and optimize supply chain operations. The company derives revenue from five sources: (i) subscription fees, (ii) transaction-based fees, (iii) professional services fees, (iv) license fees, and (v) hosting and maintenance fees.
Cardiol Therapeutics Inc is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. Its primary small-molecule candidate, CardiolRx, targets inflammasome pathway activation, which is involved in the development of inflammation and fibrosis in conditions such as pericarditis, myocarditis, and heart failure. The CardiolRx program includes the completed Phase II MAVERIC-Pilot study and the ongoing Phase III MAVERIC trial for the treatment of pericarditis. The ARCHER program evaluated CardiolRx in acute myocarditis through a completed Phase II study. The company is also developing CRD-38, a novel subcutaneous drug formulation for treating inflammatory heart conditions, including heart failure.